Timothy Ehrlich, chair of Gunderson Dettmer LLP’s life sciences practice group, has a strong record representing life sciences companies across their lifecycle, specializing in biotechnology, pharmaceuticals, and healthcare IT, advising on financings, strategic alliances, and M&A. Notable matters include guiding Remix Therapeutics in its $60m financing and billion-dollar collaboration with Roche, and Kelonia Therapeutics’ $800m partnership with Xyphos Biosciences.
Legal 500 Editorial commentary
Accolades
Boston Elite
Profile
Work Department
Corporate Governance and Strategy, Fund Investments in Companies, Life Sciences Licensing & Strategic Partnering, Life Sciences, Mergers and Acquisitions, Public Companies/Public Offerings, Seed, Venture and Growth Financings
Position
Tim is a partner in our Boston office and is chair of the firm’s Life Sciences practice group.
Career
Tim represents start-up, emerging growth and public life science companies in the biotechnology, pharmaceutical, medical device, diagnostics and healthcare IT industries. His practice spans the entire corporate lifecycle, from formation through liquidity, and he regularly serves as principal outside or general counsel to his clients. Tim is broadly experienced in business formation and entity selection, deal structuring, equity and debt financing transactions, general corporate and governance matters, M&A events and public offerings. Tim also has particular expertise in structuring and negotiating strategic alliances, including “bet-the-company” intellectual property collaborations and joint ventures, and providing strategic counseling and advice regarding intellectual property protection and commercialization. In addition to his company client counsel, Tim represents venture capital funds and institutional investors in their life science financing activities.
Education
- Harvard Law School, J.D. cum laude
- Princeton University, A.B., Classics summa cum laude Phi Beta Kappa
Content supplied by Gunderson Dettmer LLP
Key clients
- Remix Therapeutics, Inc.
- Kelonia Therapeutics, Inc.
- BrainChild Bio, Inc.
- Moonwalk Biosciences, Inc.
- QurAlis Corporation
- Be Biopharma
- MBrace Therapeutics
- DEM BioPharma
- Carbon Biosciences
- Kernal Bio
- Muna Therapeutics
- Photys Therapeutics
- Praxis Precision Medicines
Work highlights
- Advised Remix Therapeutics, Inc., a biotech company, in its $60m financing and a high-value collaboration with Roche, which included a $30m upfront payment and potential milestone payments exceeding $1bn.
- Advised Kelonia Therapeutics, Inc., in its $800m research collaboration and licensing agreement with Xyphos Biosciences, a subsidiary of Astellas Pharma. The agreement includes $40m upfront, $35m for additional options, milestone payments, R&D funding, and tiered royalties on future sales.
- Represented Be Biopharma in its $82m financing, backed by Bristol Myers Squibb, Takeda Ventures, and top venture firms.